Literature DB >> 18407934

Clinicopathological and prognostic relevance of uptake level using 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in primary breast cancer.

Shigeto Ueda1, Hitoshi Tsuda, Hideki Asakawa, Takashi Shigekawa, Kazuhiko Fukatsu, Nobuo Kondo, Mikio Yamamoto, Yukihiro Hama, Katsumi Tamura, Jiro Ishida, Yoshiyuki Abe, Hidetaka Mochizuki.   

Abstract

OBJECTIVE: Using integrated 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging (18F-FDG PET/CT), the clinical significance of 18F-FDG uptake was evaluated in patients with primary breast cancer.
METHODS: Clinicopathological correlation with the level of maximum standardized uptake values (SUV) 60 min obtained from preoperative 18F-FDG PET/CT were examined in 152 patients with primary breast cancer. The prognostic impact of the level of SUV was explored using simulated prognosis derived from computed program Adjuvant! in 136 (89%) patients with invasive ductal carcinoma (IDC).
RESULTS: High SUV level was significantly correlated with tumor invasive size (< or = 2 cm) (P < 0.0001), higher score of nuclear grade (P < 0.0001), nuclear atypia (P < 0.0001) and mitosis counts (P < 0.0001), negative hormone receptor status (P = 0.001), high score of c-erbB-2 expression (P = 0.006), lymph node metastasis (P = 0.002), and IDC in comparison with invasive lobular carcinoma (P = 0.004). Multivariate analyses showed tumor invasive size, nuclear grade and estrogen receptor negativity were significantly correlated with SUV in primary breast cancer (P < 0.0001,< 0.0001, and < 0.012, respectively), and nuclear grade was significantly correlated with SUV in tumors of invasive size 2 cm or less (P < 0.0001). Tumors with high SUV (cutoff value 4.0) showed higher relapse and mortality rate compared to those with low SUV (P < 0.0001).
CONCLUSIONS: High uptake of 18F-FDG would be predictive of poor prognosis in patients with primary breast cancer, and aggressive features of cancer cells in patients with early breast cancer. 18F-FDG PET/CT could be a useful tool to pre-therapeutically predict biological characteristics and baseline risk of breast cancer.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18407934     DOI: 10.1093/jjco/hyn019

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  71 in total

1.  Diagnostic and prognostic correlates of preoperative FDG PET for breast cancer.

Authors:  Vincent Vinh-Hung; Hendrik Everaert; Jan Lamote; Mia Voordeckers; Hilde van Parijs; Marian Vanhoeij; Guy Verfaillie; Christel Fontaine; Hansjoerg Vees; Osman Ratib; Georges Vlastos; Mark De Ridder
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-07-10       Impact factor: 9.236

2.  18F-fluorodeoxyglucose positron emission tomography optimizes neoadjuvant chemotherapy for primary breast cancer to achieve pathological complete response.

Authors:  Shigeto Ueda; Toshiaki Saeki; Takashi Shigekawa; Jiro Omata; Tomoyuki Moriya; Junji Yamamoto; Akihiko Osaki; Nobuko Fujiuchi; Misono Misumi; Hideki Takeuchi; Takaki Sakurai; Hitoshi Tsuda; Katsumi Tamura; Jiro Ishida; Yoshiyuki Abe; Etsuko Imabayashi; Ichiei Kuji; Hiroshi Matsuda
Journal:  Int J Clin Oncol       Date:  2011-08-10       Impact factor: 3.402

3.  FDG-PET SUVmax combined with IASLC/ATS/ERS histologic classification improves the prognostic stratification of patients with stage I lung adenocarcinoma.

Authors:  Kyuichi Kadota; Christos Colovos; Kei Suzuki; Nabil P Rizk; Mark P S Dunphy; Emily C Zabor; Camelia S Sima; Akihiko Yoshizawa; William D Travis; Valerie W Rusch; Prasad S Adusumilli
Journal:  Ann Surg Oncol       Date:  2012-05-30       Impact factor: 5.344

Review 4.  Present and future role of FDG-PET/CT imaging in the management of breast cancer.

Authors:  Kazuhiro Kitajima; Yasuo Miyoshi
Journal:  Jpn J Radiol       Date:  2016-01-05       Impact factor: 2.374

5.  Relationship Between FDG Uptake and the Platelet/lymphocyte Ratio in Patients With Breast Invasive Ductal Cancer.

Authors:  Takaaki Fujii; Shoko Tokuda; Yuko Nakazawa; Sasagu Kurozumi; Sayaka Obayashi; Reina Yajima; Ken Shirabe
Journal:  In Vivo       Date:  2020 May-Jun       Impact factor: 2.155

6.  PET/CT and breast cancer subtypes.

Authors:  Laura Gilardi; Marco Colleoni; Giovanni Paganelli
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-09       Impact factor: 9.236

7.  Correlation of breast cancer subtypes, based on estrogen receptor, progesterone receptor, and HER2, with functional imaging parameters from ⁶⁸Ga-RGD PET/CT and ¹⁸F-FDG PET/CT.

Authors:  Hai-Jeon Yoon; Keon Wook Kang; In Kook Chun; Nariya Cho; Seock-Ah Im; Sunjoo Jeong; Song Lee; Kyeong Cheon Jung; Yun-Sang Lee; Jae Min Jeong; Dong Soo Lee; June-Key Chung; Woo Kyung Moon
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-03-21       Impact factor: 9.236

8.  18F-FDG uptake in breast cancer correlates with immunohistochemically defined subtypes.

Authors:  Hye Ryoung Koo; Jeong Seon Park; Keon Wook Kang; Nariya Cho; Jung Min Chang; Min Sun Bae; Won Hwa Kim; Su Hyun Lee; Mi Young Kim; Jin You Kim; Mirinae Seo; Woo Kyung Moon
Journal:  Eur Radiol       Date:  2013-10-05       Impact factor: 5.315

9.  A case of primary lung cancer lesion demonstrated by F-18 FDG positron emission tomography/computed tomography (PET/CT) one year after the detection of metastatic brain tumor.

Authors:  Yuichi Ozeki; Yoshiyuki Abe; Hideyuki Kita; Katsumi Tamura; Ikuko Sakata; Jiro Ishida; Kikuo Machida
Journal:  Oncol Lett       Date:  2011-05-16       Impact factor: 2.967

Review 10.  18F-FDG uptake in lung, breast, and colon cancers: molecular biology correlates and disease characterization.

Authors:  Hossein Jadvar; Abass Alavi; Sanjiv S Gambhir
Journal:  J Nucl Med       Date:  2009-10-16       Impact factor: 10.057

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.